Daiichi Sankyo Europe GmbH
Budget
€900 — €0
EP Access
1
accredited persons
Staff
3
1.5 FTE
EU Grants
None
Mission & Goals
Daiichi Sankyo is a research-based global pharmaceutical company headquartered in Japan with operations in more than 20 countries worldwide. The European headquarters are located in Munich; mainly active in the areas of cardiovascular diseases & oncology.
EU Legislative Interests
Daiichi Sankyo is interested in EU initiatives and political developments that relate to our focus in research, development, manufacturing and business: innovative medicines. This includes topics such as health policy, global health, , relevant pharmaceutical legislation including General Pharmaceutical Legislation, Biotech Act I, Urban Wastewater Treatment Directive, Critical Medicines Act, EU Safe Hearts Plan, clinical trials, trade, IP, environment and sustainability.
Communication Activities
Sponsorship and report of Economist World Cancer Series - session on Women Centric Breast Cancer Care. European Health Forum Gastein with session on NCD's and women's health, European Business Summit - session on EU Cardiovascular Health Plan, Online roundtable with European Cancer Organisation on breast cancer - sponsored.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Efpia (https://www.efpia.eu/) EPC (https://www.epc.eu/en) European Cancer Organisation (E.C.O.) (https://www.europeancancer.org/) EAPM (European Alliance for Personalised Medicine) (https://www.euapm.eu/) Japanese Business Council (https://www.jbce.org/en/) All.Can (https://www.all-can.org/)
Organisation Members
https://www.daiichi-sankyo.eu/
Commissioner Meetings
No recorded meetings with EU commissioners.